Highlights

  • Miro Sciences (ASX:MSX) has announced the completion of a TGA inspection of its Manufacturing partner Q-Gen Cell Therapeutics, a key step toward clinical trial Supply of StemSmart.
  • The completed inspection supports Miro Sciences' preparations for a planned Phase 2 clinical trial in refractory Crohn's disease for patients in Australia and the United States.
  • Q-Gen Cell Therapeutics, located within QIMR Berghofer in Brisbane, is one of Australia's largest cell therapy contract manufacturers, with 13 dedicated cleanrooms.
  • Miro Sciences is targeting trial initiation by the end of calendar year 2026, following recent positive FDA feedback and the appointment of Southern Star Research as clinical research organisation.

Miro Sciences Limited (ASX:MSX), formerly NeuroScientific Biopharmaceuticals, has announced the completion of the Therapeutic Goods Administration (TGA) inspection of Q-Gen Cell Therapeutics, its designated manufacturing partner for the StemSmart stem cell product. The company described this milestone as a significant step in the manufacturing and regulatory pathway associated with the supply of StemSmart for the planned Phase 2 clinical trial in refractory Crohn's disease.

Latest Development

The TGA performs audit inspections of manufacturing procedures and facilities to ensure compliance with regulatory standards applicable to the clinical trial supply of therapeutic goods for Australian patients. The completion of this audit at Q-Gen represents one of the critical steps in the technology transfer of Miro Sciences' StemSmart product to Q-Gen, which is intended to scale up supply for the planned Phase 2 clinical trial in Australia and the United States, subject to regulatory approvals.

About StemSmart and the Clinical Program

StemSmart is Miro Sciences' proprietary stem cell technology platform, based on adult human donor bone marrow-sourced mesenchymal stem cells (MSCs). The product was developed at the Royal Perth Hospital in Western Australia and is produced using a patented manufacturing process designed to improve therapeutic activity and clinical response in severe inflammatory conditions. Early data from a previous Phase 2 trial in refractory Crohn's disease indicated that StemSmart MSCs demonstrated potency, efficacy, and an acceptable safety profile, according to the company.

Crohn's disease is a chronic inflammatory bowel condition that can be severely debilitating, with a subset of patients remaining refractory — that is, unresponsive — to current standard therapies. StemSmart is being developed specifically for patients in this treatment-resistant category, where the medical need remains substantial.

Manufacturing and Regulatory Progress

Q-Gen Cell Therapeutics is based within QIMR Berghofer in Brisbane, one of Australia's largest medical research institutes. Q-Gen holds a TGA licence for cell therapy manufacture and brings more than 25 years of experience in cell therapy manufacturing for industry. Its Facility features 13 cleanrooms dedicated to cell manufacturing and quality control, providing the infrastructure needed to scale production for a Phase 2 trial.

The TGA inspection is part of a broader series of regulatory and manufacturing activities being progressed by Miro Sciences. Prior milestones include the appointment of Southern Star Research as clinical research organisation for the Phase 2 trial, announced in October 2026, and positive feedback from the FDA on the company's Pre-Investigational New Drug (Pre-IND) submission meeting.

Development Timeline

Miro Sciences is targeting trial initiation by the end of calendar year 2026, with the Phase 2 program intended to enrol patients in both Australia and the United States. The Chief Scientific Officer, Dr Marian Sturm — the inventor of the StemSmart technology — noted that the successful TGA inspection of manufacturing represents progress toward TGA licensure of the company's MSC product.

Company Background

Miro Sciences describes itself as a biotechnology company focused on the development of novel therapeutics targeting immune-mediated inflammatory disorders. The company's research centres on modulating pathological immune responses involved in chronic and degenerative conditions, particularly where current therapeutic Options demonstrate limited efficacy or durability.

Sector Context

Cell therapy represents one of the most rapidly evolving areas of biopharmaceutical development, with mesenchymal stem cells attracting attention for applications in inflammatory and autoimmune conditions. Manufacturing scalability has historically been a key challenge in cell therapy development, and the successful transfer of production to an experienced contract manufacturer like Q-Gen is considered a meaningful step in commercialisation readiness.

Growth Drivers

For Miro Sciences, the successful completion of the TGA inspection, combined with FDA engagement and CRO appointment, reflects a convergence of key readiness steps ahead of clinical commencement. If the Phase 2 trial initiates as planned and generates supportive safety and efficacy signals, it would position the company to pursue further regulatory discussions in both Australia and the United States.

Risks and Challenges

Cell therapy development involves complex manufacturing and regulatory pathways. The TGA licensure process for Q-Gen is ongoing, and the final supply of StemSmart for the trial remains subject to regulatory approvals. Clinical Trials in Crohn's disease can be challenging to enrol due to the specificity of the target population — treatment-resistant patients who meet the trial's eligibility criteria. Additionally, early-phase trial results may not translate to later-stage efficacy.

Investor Considerations

For investors following Miro Sciences, the convergence of TGA manufacturing milestone, positive FDA Pre-IND feedback, and CRO appointment represents a meaningful clustering of readiness indicators ahead of Phase 2 trial initiation. Each of these steps reduces the risk of unanticipated delays in getting the first patient dosed. The targeting of trial initiation by the end of calendar year 2026 is an ambitious timeline, though the company has indicated that all operational preparations are progressing in a coordinated manner. Refractory Crohn's disease is a condition with limited treatment options for a subset of patients, and there is genuine unmet clinical need that motivates Investment in novel therapies like StemSmart. For small-cap biotech investors, the key milestones to monitor include formal trial initiation confirmation and, subsequently, any interim safety readouts from the Phase 2 program in Australia and the United States.

Key Insights

Miro Sciences has completed a critical regulatory milestone with the TGA inspection of its manufacturing partner, Q-Gen Cell Therapeutics. Combined with recent positive FDA feedback and CRO appointment, the company is building toward its targeted Phase 2 trial initiation for StemSmart in refractory Crohn's disease by the end of calendar year 2026. Each completed step in the manufacturing and regulatory pathway reduces the gap between the company's current development stage and clinical commencement.